In a phase 1 study, trastuzumab deruxtecan was tested at a dose of 5.4 mg or 6.4 mg/kg in 111 patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine [43]. This evidence concerns the gene ERBB2 and breast carcinoma.